Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Fabry Disease Registry

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Sanofi
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company ) Identifier:
First received: September 13, 2005
Last updated: July 8, 2016
Last verified: July 2016

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.

The objectives of the Registry are:

  • To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;
  • To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;
  • To characterize and describe the Fabry population as a whole; and
  • To evaluate the long-term safety and effectiveness of Fabrazyme®

Fabry Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Fabry Disease Registry

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • To evaluate the long-term safety and effectiveness of Fabrazyme® [ Time Frame: 15 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 9000
Study Start Date: July 2001
Estimated Study Completion Date: July 2030
Estimated Primary Completion Date: July 2030 (Final data collection date for primary outcome measure)
Detailed Description:

The Fabry Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact:

  • In Asia-Pacific - Vivian Liu, +65-6431-2548,
  • In Europe - +31-35-699-1232,
  • In Latin America - +617-591-5500,
  • In North America - +617-591-5500,

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with a confirmed diagnosis of Fabry disease are eligible for inclusion in the Registry.

Inclusion Criteria All patients with a confirmed diagnosis of Fabry disease who have signed the informed consent and patient authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as a documented deficiency in plasma or leukocyte αGAL (alpha-galactosidase) enzyme activity and/or mutation(s) in the gene coding for αGAL.

Exclusion Criteria There are no exclusion criteria in this Registry. Patients are allowed to participate in other clinical studies and may be receiving different therapies to treat their disease; however, enrollment in other clinical studies should be noted on the Registry case report forms (CRFs).

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00196742

Contact: For site information, send an email with site number to
Contact: Fabry Registry HelpLine 617-591-5500

  Show 64 Study Locations
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Genzyme, a Sanofi Company Identifier: NCT00196742     History of Changes
Other Study ID Numbers: FABRY REGISTRY  DIREGC07006 
Study First Received: September 13, 2005
Last Updated: July 8, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Sanofi:
alpha Galactosidase A
aGAL (alpha-galactosidase)
GL3 (globotriaosylceramide)
Anderson-Fabry Disease
GLA deficiency (gene deficiency)
errors in metabolism

Additional relevant MeSH terms:
Fabry Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders processed this record on October 21, 2016